Providing comprehensive care to all children and adolescents

We are migrating to a new electronic medical record and patient portal platform

We have started to receive our 2026 supplies of Beyfortus , a single-dose monoclonal antibody injection that protects against severe disease from Respiratory Syncytial Virus (RSV) . The AAP recommends that ALL infants under age 8 months entering their first RSV season (birthday March 1, 2026 or later), whose mother HAS NOT received an RSV vaccine, should receive a single dose of Beyfortus from October 1, 2026 through March 31, 2027 Beyfortus is also recommended for a small group of children between 8 and 19 months who are at risk for severe RSV disease (premature infants with chronic lung disease; children severely immunocompromised; children with severe cystic fibrosis; Native American or Alaskan children). The immunization can be given as part of the well visit and IS SAFE to combine with any other recommended immunization, including COVID and Flu vaccine. Pregnant mothers are generally offered an RSV vaccine, Abrysvo, starting in September and when they are between 32 and 36 weeks of gestation. If a mother received this vaccine at least 14 days prior to delivering, then her infant is considered protected and DOES NOT need to receive Beyfortus as well. If your child does not have an upcoming well visit, then Beyfortus can be given at a nurse shot visit.